Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA application process
Fierce Pharma
Novo’s Catalent plant ditched in FDA refiling of SMA drug
A recent FDA inspection of Novo's troubled Catalent site in Indiana has been classified as “Official Action Indicated.”
Angus Liu
Aug 10, 2026 10:06am
J&J files for FDA approval of $6.5B autoimmune drug
Aug 29, 2024 8:57am
Reata has wait for FDA ataxia drug decision delayed by 3 months
Aug 9, 2022 9:52am
TG's pivot to MS faces setback as FDA pushes approval
May 31, 2022 9:40am
Incyte pulls approval filing, following Gilead out of the exitIn
Jan 26, 2022 7:30am
Biogen, Sage plot 2022 filing for zuranolone approval
Oct 19, 2021 7:50am
